Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80

Piper Sandler analyst David Westenberg has maintained a Neutral rating on 10x Genomics (NASDAQ: TXG) while raising the price target from $47 to $80. This adjustment reflects a positive outlook on the company's performance.